NASDAQ: PCVX

Vaxcyte (PCVX) Stock Analysis & Forecast

Nov 13 close

$63.37−1.32 (−2.0%)

Gekko Brief

AI summaryNov 9 close

Vaxcyte's shares climbed this week after the company announced positive topline OPUS-1 Phase 3 data for its VAX-31 pneumococcal vaccine candidate in adults, meeting all primary endpoints with a safety profile similar to existing vaccines. The move was reinforced by a Q3 report in which Vaxcyte topped EPS estimates, posting a loss of ($1.99) against a ($2.13) estimate, even as nine-month operating cash use topped $737 million and the net loss widened to $297.1 million from $212.8 million a year earlier. BTIG maintained a Buy rating with an $89.00 price target following the news.

Shares closed at $67.53, up 5.7%, sitting above both the 50-day average of $61.86 and the 200-day average of $57.45. The GekkoIndex reading of 53.7 places the stock in the Neutral zone, down 6.8 over the past five readings. Price remains 18.3% below Gekko Fair Value of $82.7, a gap that has widened rather than closed despite the week's rally.

The next earnings date falls on 23 February 2027, well outside a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality skews unfavorable, with the next 20 trading days averaging -1% over 5 years and rising in only 2 of them. Analyst sentiment remains heavily tilted toward Buy ratings, with a consensus target of $117.3 implying notable upside.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Vaxcyte price vs fair value

$82.69$63.37Nov ’25May ’26Nov ’26
Close $63.37200-day averageGekko Fair Value $82.69

Vaxcyte quick facts

Market cap
$10.03B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$8.05
Revenue, TTM
$0
Profit margin
0%
Dividend yield
—
Beta
1.29
Volume
623,283 avg 1.89M
1-year return
+37.5%
Typical daily move
±4.8%
Typical 20-day move
±8.7%
50-day average
$62.24
200-day average
$57.70
Next earnings
Feb 23 after close
Shares outstanding
158.3M
52-week range
$42.40$90.75

Vaxcyte swing-trade checklist

Vaxcyte scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $63.37 is above the 50-day ($62.24) and 200-day ($57.70) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    57.1, Neutral

    Reading 57.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuesupportive

    23.4% below

    Price is 23.4% below Gekko Fair Value (more than 5% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalityheadwind

    −2.5% on average

    From this point in the calendar, the next 20 trading days averaged −2.5% over 5 years, rising in 2 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Vaxcyte stock chart and price history

Vaxcyte closed at $63.37 on Nov 13, 2026, +37.5% over the past year, inside a 52-week range of $42.40 to $90.75.

Close50-day average200-day averageVolume
Vaxcyte share price, past year, with 50-day and 200-day moving averages and volume$40$50$60$70DecJan 2026FebMarAprMayJunJulAugSepOctNov63.37

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
−2.9%
3 months
+5.2%
6 months
+21.0%
1 year
+37.5%
The full PCVX chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PCVX in Gekko

Follow Vaxcyte through every session

Put PCVX on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track PCVX in GekkoFree for 7 days. No credit card required.

About Vaxcyte

Vaxcyte works in early-stage biotechnology, focused on building protein-based vaccines aimed at preventing or treating bacterial infections. Its furthest-along program, VAX-24, is a 24-valent pneumococcal conjugate vaccine in Phase 1/2 testing meant to guard against invasive pneumococcal disease and pneumonia. The company is best recognized for this pneumococcal vaccine work within its broader research pipeline.

Alongside VAX-24, Vaxcyte is developing several other vaccine candidates. VAX-XP targets emerging bacterial strains and antimicrobial resistance, VAX-A1 is a conjugate vaccine aimed at Group A Streptococcus, and VAX-PG is designed against the bacterium linked to periodontitis. The company's activities center on advancing these candidates through clinical development rather than on selling approved products.

Vaxcyte was founded in 2013 under the name SutroVax, Inc., adopting its current name in May 2020. It is headquartered in San Carlos, California, and its shares trade on the NASDAQ under the ticker PCVX.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
vaxcyte.com

Vaxcyte GekkoIndex: the smart money zone

Vaxcyte’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57.1, in the Neutral zone, up 0.7 points over five sessions.

010057.1Neutral

Up 0.7 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying35+0.8%+0.6%−1.2%+2.0%
Accumulation235−0.9%−1.0%−0.6%+1.3%
Neutral (current zone)393+1.2%+1.9%+3.0%+5.4%
Distribution320.0%+0.1%−0.2%−4.7%
Selling7Too few readings yet

Average PCVX share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the PCVX price, zone by zone.Track PCVX in Gekko

Is Vaxcyte stock overvalued? Gekko Fair Value

Vaxcyte trades 23.4% below Gekko Fair Value of $82.69, so the shares are undervalued on Gekko’s estimate.

Gekko’s own estimate of what Vaxcyte shares are worth, recalculated every trading day.

$82.69

Gekko Fair Value, Nov 14, 2026

23.4% Undervalued

At the end of Aug 2026 the price was 33.2% below the estimate.

Gekko Fair ValueShare price, month end
$83$63Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open PCVX in Gekko

Vaxcyte insider and Congress trading

No open-market insider purchases were filed for Vaxcyte, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for PCVX in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every PCVX insider filing, plotted on the chart in Gekko.Open PCVX in Gekko

Congress trades last 90 days

No trades in PCVX were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for PCVX, plotted on the chart in Gekko.Open PCVX in Gekko

Hedge funds and billionaires quarter ended Jun 30

0of the funds Gekko tracks hold PCVX.

0added0opened0trimmed2sold out
Which funds are on each side, name by name.Unlock in Gekko

Vaxcyte earnings: next date and track record

Vaxcyte reports on Feb 23, 2027, after the close (100 days away), and beat the EPS estimate in 2 of its last 8 reports.

2 of 8reports beat the EPS estimate
±6.3%average move across the report
3 of 8reports followed by a gain

Share-price move across each report

−2.3%Nov ’24−3.7%Feb ’25+7.6%May ’25−11.0%Aug ’25−5.9%Nov ’25+4.6%Feb ’26−7.5%May ’26+7.7%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026−$1.97
est −$2.06
+4.4%—
est $12.50M
—+7.7%
May 6, 2026−$2.30
est −$1.78
−29.4%—
est $12.50M
—−7.5%
Feb 24, 2026−$1.80
est −$1.53
−17.7%—
est $18.75M
—+4.6%
Nov 4, 2025−$1.56
est −$1.27
−22.8%——−5.9%
Aug 6, 2025−$1.22
est −$1.12
−8.9%——−11.0%
May 7, 2025−$1.04
est −$1.02
−2.0%——+7.6%
Feb 25, 2025−$1.02
est −$0.99
−2.6%——−3.7%
Nov 5, 2024−$0.83
est −$1.10
+24.5%——−2.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Vaxcyte stock forecast and analyst price targets

Analysts’ average 12-month price target for Vaxcyte is $116.40, +83.7% from the last close, from 10 firms rating the stock in the last 90 days.

$116.40consensus 12-month target, +83.7% from the last close
Low $75High $163
Buy9
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 10 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 5TD CowenBuy, maintained$75+18.4%
Nov 5Leerink PartnersBuy, maintained$102+61.0%
Nov 5Bank of America SecuritiesBuy, maintained——
Nov 4BTIGBuy, maintained$89+40.4%
Oct 12Cantor FitzgeraldBuy, maintained$120+89.4%
+3.0%average 20-day move after past Neutral readings
−2.5%average move over the next 20 trading days in the last 5 years
±4.8%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Vaxcyte seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Vaxcyte averaged −2.5% across the last 5 years, rising in 2 of them.

Next 20 trading days, by year

−17.3%2021+3.0%2022+19.6%2023−5.4%2024−8.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−5.1%2 of 5
Next 10 trading days−5.7%2 of 5
Next 15 trading days−3.6%1 of 5
Next 20 trading days−2.5%2 of 5
Next 30 trading days+0.4%2 of 5

For scale, PCVX’s typical 20-trading-day move in either direction is about 8.7%.

Vaxcyte market cap and key statistics

Vaxcyte’s market cap is $10.03B and revenue of $0 over the last twelve months.

Valuation

Market cap
$10.03B
EPS, TTM
−$8.05
Gekko Fair Value
$82.69

Trading

Volume
623,283
Avg volume, 20 days
1.89M
52-week high
$90.75
52-week low
$42.40
Shares outstanding
158.3M

Financials

Revenue, TTM
$0
Profit margin
0%
Return on equity
-42.7%
Quarterly earnings growth, YoY
0.0%

Risk and income

Beta
1.29
Typical daily move
±4.8%
Typical 20-day move
±8.7%

Vaxcyte stock news this week

Coverage of Vaxcyte this week reads positive: 4 positive, 4 neutral and 1 negative headlines.

News sentiment positive

Vaxcyte peers

Vaxcyte’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Vaxcyte stock FAQ

What is Vaxcyte’s market cap?

Vaxcyte’s market cap is $10.03B at the Nov 13, 2026 close of $63.37, with 158.3M shares outstanding.

What is the Vaxcyte stock forecast?

The consensus analyst 12-month price target for Vaxcyte is $116.40, +83.7% from the last close. Of the 10 firms that rated the stock in the last 90 days, 9 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Vaxcyte stock overvalued or undervalued?

On Gekko’s estimate Vaxcyte is undervalued: the Nov 13, 2026 close of $63.37 is 23.4% below Gekko Fair Value of $82.69. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Vaxcyte report earnings next?

Vaxcyte is expected to report on Feb 23, 2027, after the market closes (100 days away). Analysts expect earnings of −$1.92 per share on revenue of $12.50M. Vaxcyte beat the earnings estimate in 2 of its last 8 reports, moving 6.3% on average across the report.

What is Vaxcyte’s 52-week high and low?

Vaxcyte’s 52-week high is $90.75 and its 52-week low is $42.40; it closed at $63.37 on Nov 13, 2026, +37.5% over the past year. Over the last five years the shares peaked at $121.06 on Sep 19, 2024.

Is Vaxcyte stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, fair value and earnings risk), 1 as mixed (gekkoindex) and 1 as a headwind (seasonality). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Vaxcyte the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.